RNA sequencing of LX-2 cells treated with TGF-β1 identifies genes associated with hepatic stellate cell activation

Jack P. Carson1 · Mark W. Robinson1 · Grant A. Ramm2,3 · Geoffrey N. Gobert1

Received: 1 June 2021 / Accepted: 14 September 2021 / Published online: 14 October 2021
© The Author(s) 2021

Abstract

Background  Hepatic stellate cells (HSCs) are liver-resident myofibroblast precursors responsible for the production of collagen and maintenance of the hepatic extracellular matrix (ECM). As such, they are generally associated with fibrotic liver diseases. HSCs become “activated” in response to tissue damage or pathogen invasion, a process most commonly driven by transforming growth factor-β1 (TGF-β1). Despite this, the full extent of TGF-β1 signalling in these cells is poorly understood. Clarifying the range and diversity of this signalling will further improve our understanding of the process of HSC activation.

Methods and results  RNA sequencing was used to quantitate the transcriptomic changes induced in LX-2 cells, an activated human HSC line, following TGF-b1 treatment. In total, 5,258 genes were found to be significantly differentially expressed with a false discovery rate cut-off of < 0.1. The topmost deregulated of these genes included those with no currently characterised role in either HSC activation or fibrotic processes, including CIITA and SERPINB2. In silico analysis revealed the prominent signalling pathways downstream of TGF-β1 in LX-2 cells.

Conclusions  In this study, we describe the genes and signalling pathways significantly deregulated in LX-2 cells following TGF-β1 treatment. We identified several highly deregulated genes with no currently characterised role in HSC activation, which may represent novel mediators of fibrotic responses in HSCs or the liver macroenvironment. This work may be of use in the identification of new markers of liver fibrosis and could provide insight into prospective genes or pathways that might be targeted for the amelioration of fibrotic liver disease in the future.

Keywords  Hepatic stellate cell · LX-2 · Transforming growth factor-β1 · Fibrosis · Chronic liver disease.

Abbreviations

ACTA2  α-smooth muscle actin
aHSC  activated hepatic stellate cell, myofibroblast
ALD  alcoholic liver disease
CIITA  class II major histocompatibility complex transactivator
COL1A1  collagen type 1 chain 1
ECM  extracellular matrix
EGR2  Early growth response 2
EIF2  eukaryotic initiation factor 2
FAP  fibroblast activation protein
FDR  false discovery rate
FN1  fibronectin 1
FOXS1  forkhead box S1
HCV  hepatitis C virus
HES1  hes family BHLH transcription factor 1
HSC  hepatic stellate cell
ISLR2  immunoglobulin superfamily cont. leucine rich repeat 2
KRT3  keratin 3
MHCII  major histocompatibility complex class II
NAFLD  non-alcoholic fatty liver disease
NASH  non-alcoholic steatohepatitis
NOX4  NADPH oxidase 4
Introduction

Fibrosis can be defined as the excessive deposition of ECM proteins, particularly fibrillar collagens, within a tissue [1]. In the liver, ECM protein deposition is often provoked by injury or disease, where it assists tissue regeneration and limits the spread of harmful pathogens [2]. Despite these benefits, the development of fibrosis can often have pathological consequences; the accumulation of excessive amounts of ECM proteins can result in tissue congestion, which disrupts blood flow and compromises organ function [1, 3]. If the provoking agent persists, fibrosis can further develop into a chronic condition resulting in severe changes to the liver architecture and ultimately leading to cirrhosis, liver failure and death [1, 4]. Liver fibrosis is a common pathology of several diseases, including chronic hepatitis C virus (HCV) infection, alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD)-derived non-alcoholic steatohepatitis (NASH) and some parasitic diseases (schistosomiasis).

HSCs are a population of myofibroblast precursors located within the space of Dissé in the liver sinusoids [5]. HSCs represent 5–8% of all liver cells [6] and store ~ 80% of the body’s total vitamin A. Upon receiving stimuli in response to either liver damage or disease, these normally quiescent storage cells undergo a process of transdifferentiation, or “activation”, into myofibroblasts (aHSCs) [5]. Following activation, HSCs lose their ability to store vitamin A, develop a broader ‘stretched’ cytoplasm supported by filaments of α-smooth muscle actin (ACTA2), and adopt roles involved in tissue regeneration and the immune response against invading pathogens [5, 7]. The primary role of myofibroblasts is the production of collagen and other ECM components, and as such aHSCs are the main cell population responsible for fibrogenesis in the liver [4].

HSCs are driven to activate in response to a wide variety of cellular and pathogen-derived stimuli. These stimuli can include cellular components such as growth factors, interleukins, reactive oxygen species or damage-associated molecular patterns; and proteins, DNA or lipopolysaccharide from pathogens [8]. The various mechanisms of HSC activation have been reviewed by Tsuchida and Friedman [8]. The type of response levied by HSCs is largely dependent on the specific activating stimulus [4, 8]. A major driver of both HSC activation and liver fibrogenesis is the cytokine TGF-β1 [9, 10]. This cytokine is almost ubiquitously expressed throughout mammalian tissues and is involved in a wide variety of critical physiological processes, including both immune and inflammatory responses, cell differentiation and tissue repair [10].

HSCs often play conflicting roles within the context of liver damage or disease. Their ability to produce ECM components makes HSCs critical in tissue regeneration and, due to the immunologically relevant cytokines and chemokines they produce, they are also important in the response against invading pathogens [5, 7]. However, their primary role of ECM protein synthesis also renders them responsible for the fibrosis, and fibrosis-related pathology and morbidity, associated with many chronic liver diseases [4].

TGF-β1 signalling in HSCs has yet to be explored in-depth at the transcriptomic level. Herein we will describe the application of RNA sequencing and in silico pathway analysis to identify the initial genes and signalling pathways that are most strongly deregulated by TGF-β1 treatment in LX-2 cells, an immortalised human HSC line that retains many important features of primary HSCs [11]. This work should improve the understanding of the transcriptional processes associated with HSC activation. Given the involvement of aHSCs in liver disease, these findings may provide new insights into the gene networks involved in fibrogenesis that could be exploited as fibrotic markers or as the targets of therapeutics.

Materials and methods

Cell culture

LX-2 cells (Merck Millipore, Burlington, USA), an immortalised human aHSC line [11], were maintained in Dulbecco’s modified eagle medium (DMEM, ThermoFisher Scientific, Waltham, USA) supplemented with 2% foetal bovine serum (FBS, Sigma-Aldrich, St. Louis, USA), 100 units/ml penicillin/streptomycin (ThermoFisher Scientific) and 4 mM L-glutamine (L-Glu, ThermoFisher Scientific) at 37 °C and 5% CO2. Upon reaching ~ 80% confluency, LX-2 cells were detached from the culture flask using 0.25% trypsin-EDTA solution (ThermoFisher Scientific) and re-seeded according to a split ratio of 1:3.
Immunofluorescence

Cells were seeded in 48-well cell culture plates (ThermoFisher Scientific) at a density of ~10,000 cells per well, cultured in DMEM with supplements and treated with 2.5 ng/ml TGF-β1 [12] (InvivoGen, San Diego, USA) where appropriate for 72 h. Cells were then fixed and permeabilised in ice cold methanol for 5 min, washed three times in phosphate-buffered saline (PBS) for 5 min each and blocked in 5% bovine serum albumin (BSA, Sigma-Aldrich) in PBS (Sigma-Aldrich) for 30 min at room temperature. Cells were then incubated overnight at 4 °C in primary antibody (ACTA2, 1:250 dilution, Abcam ab5694, Cambridge, UK) diluted in 5% BSA in PBS. The following day the cells were washed three times in PBS for 5 min each, incubated with secondary antibody (goat anti-rabbit IgG H&L, Alexa Fluor® 488, 1:1000 dilution, Abcam ab150077) diluted in 5% BSA in PBS for 1 h at room temperature, washed three times again and then incubated with 4’,6-diamidino-2-phenylindole (DAPI) solution (1:1000 dilution in PBS) for 15 min at room temperature. The cells were washed for a final three times and lastly covered with 250 µl of clean PBS prior to imaging. Images were taken on a total internal reflection fluorescence microscope (Leica, Wetzlar, Germany) in standard fluorescent mode.

RNA isolation

Cells were seeded in 6-well cell culture plates (ThermoFisher Scientific) at a density of ~100,000 cells per well and cultured in DMEM with supplements for 24 h. At this time, the media was removed, and the cells were gently rinsed 3 times with warm PBS. The cells were then serum starved overnight in serum-starvation media (DMEM supplemented with 0.1% FBS, 1 unit/ml penicillin/streptomycin and 4 mM L-Glu). The following morning, 2.5 ng/ml TGF-β1 [12] was added to the cells where appropriate. Cells were cultured for a further 24 h, after which the media was removed, and the cells were rinsed 3 times with cold PBS. Total RNA was isolated from the cells using the GenElute Mammalian Total RNA Miniprep Kit (Sigma–Aldrich). Genomic DNA was digested during this process using the On-Column DNase I Digestion Set (Sigma-Aldrich). RNA purity was assessed using the POLARstar Omega (BMG Labtech, Cary, USA), and samples (in technical triplicate) from non-treated and TGF-β1-treated LX-2 cells with a 260/280 ratio ≥ 1.9 were submitted for RNA sequencing.

RNA sequencing pipeline

This work was performed by the Genomics Central Technology Unit (GCTU) of Queen’s University Belfast. RNA sequencing libraries were generated using an automated KAPA RNA HyperPrep kit with riboerase protocol (Roche, Basel, Switzerland) according to the manufacturer’s instructions on the Beckman FXp robot (Beckman Coulter, Indianapolis, USA). Sequencing was performed on the Illumina Next-Seq 550 platform (Illumina, California, USA) using a 75 base-pair single-read flow cell. An average of 21,559,518 reads were obtained across all samples. Sequencing data was aligned to the human reference genome (assembly GRCh37, BioProject accession PRJNA31257) using the STAR aligner (version 2.7) [13] in Linux, and gene counts were calculated from the alignment data using HTSeq (version 0.11.1) [14]. Differential expression analysis was carried out on the data received from the GCTU using the DESeq2 (version 3.11) [15] analysis package in R (version 3.5.3) [16] with default settings applied.

Pathway analysis

Pathway analysis was carried out on the gene expression data using Ingenuity Pathway Analysis (IPA) [17] software (Qiagen, Hilden, Germany). Genes were first mapped to the IPA knowledgebase, and the “core analysis” function was used to predict the canonical pathways that data set genes are associated with based on the gene fold change and false discovery rate (FDR) measurements. All analyses were carried out against the human knowledgebase with default settings applied. Changes in the activity of signalling pathways were quantified by the z-score, a value calculated through pathway analysis. The z-score is a directional measurement based on several factors, including the fold changes of the genes associated with a pathway, and the ratio of pathway genes present in the data set vs. those involved in the pathway overall [18]. A positive z-score indicates the pathway in question is more active compared to controls.

Results

TGF-β1 increased the formation of ACTA2 filaments in LX-2 cells

The upregulated expression of ACTA2 and formation of organised ACTA2 filaments are common markers of myofibroblasts [5]. The presence of ACTA2 filaments within LX-2 cells was examined to confirm their activation following TGF-β1 exposure. Fluorescent microscopy (Fig. 1) confirmed that both the expression and the filament distribution of ACTA2 were clearly increased by TGF-β1 treatment.

Differentially expressed genes in LX-2 cells following TGF-β1 treatment

The expression of 17,821 genes were detected in LX-2 cells. Of these genes, 5258 were observed to undergo statistically
significant (FDR < 0.1) changes in expression following TGF-β1 treatment (2721 upregulated, 2537 downregulated). Figure 2 shows a volcano plot of the distribution of these genes. Tables 1 and 2 show the 25 most up- and downregulated genes detected in LX-2 cells following TGF-β1 treatment, respectively. The most upregulated genes included ISLR2 (fold change 324.03, FDR 6.06E-11) and KRT3 (fold change 56.49, FDR 1.71E-04). The most downregulated genes included SOX3 (fold change −33.33, FDR 1.58E-03) and NR5A2 (fold change −25.00, FDR 5.29E-06).

**Signalling pathways deregulated by TGF-β1 in LX-2 cells**

Overall, the activity of 323 signalling pathways were predicted to be significantly (p value < 0.05) altered by TGF-β1 in LX-2 cells. The directional prediction of pathways with a z-score of between 2 and −2 was assumed to be non-significant based on previous studies [18] and so these pathways were discounted. Figures 3 and 4 show the 15 most up- and downregulated pathways, respectively. The five most upregulated pathways included “tRNA charging” (z-score= 4.6), “EIF2 signalling” (z-score= 4.272), “ERK5 signalling” (z-score= 3.087), “actin nucleation by ARP-WASP complex” (z-score= 3.053) and “PI3K/AKT signalling” (z-score= 3.048). The five most downregulated pathways included “PPARα/RXRα activation” (z-score= −3.414), “apelin cardiac fibroblast signalling pathway” (z-score= −3.162), “neuropathic pain signalling in dorsal horn neurons” (z-score = 3), “PTEN signalling” (z-score = 2.734) and “ethanol degradation IV” (z-score= −2.53).

**Discussion**

Fibrosis is a pathology associated with many liver diseases, particularly chronic conditions, that can develop into cirrhosis, liver failure and death if left untreated [4].
Liver fibrogenesis often occurs when HSCs become activated following liver damage or disease and respond with the secretion of ECM proteins [19]. HSCs can activate in response to a range of stimuli, with one of the most common being TGF-β1 [9, 10]. TGF-β1 is a potent cytokine expressed throughout mammalian tissues, and is involved in a wide variety of key cellular processes [10]. Despite the physiological importance of TGF-β1 and its potent HSC activating ability, the specific responses the cytokine induces in HSCs have yet to be fully characterised due to the complexity and far reaching nature of TGF-β1 signalling [1].

Several studies have explored HSC activation at the transcriptomic level using various methods and cell lines [20–25]. The first such study utilised microarray analysis to investigate the effects of culture-induced activation (where HSCs activate over time on tissue culture plastic) on gene expression in LX90 cells, another immortalised human HSC line, when cultured on Matrigel [24]. This study identified 3350 differentially expressed genes and led to the identification of myocardin as an activator of HSCs [24]. A second study used RNA sequencing of primary human foetal HSCs exposed to TGF-β1 to identify differentially expressed long non-coding RNAs (lncRNAs) [21]. This study found that TGF-β1 influences the expression of 381 lncRNAs in human foetal HSCs [21]. Another RNA sequencing study investigated the differences in gene expression between quiescent and culture-activated primary human HSCs, with valproic...
acid used to maintain quiescence [20]. Overall, the differential expression of 5,449 genes were detected and three genes which regulate the expression of connective tissue growth factor, fibroblast growth factor 2 and netrin 4, each associated with HSC activation and liver fibrosis, were identified [20]. RNA sequencing has also been applied to assaying the transcriptomic effects of anti-fibrotic molecules on HSCs with the aim of identifying potential therapeutics for liver fibrosis [26].

As noted by Gerhard et al., the aim of these studies can be put simply as characterising the changes in gene expression that occur in HSCs during activation, and yet the findings show a large amount of variation in both the identity and number of differentially expressed genes [25]. It is clear that the methods used to provoke HSC quiescence or activation, and detect gene expression, as well as the specific cell lines assayed, have a strong impact on the final results [25].

A summary of the effects of TGF-β1 on the genes and signalling pathways discussed below can be found in Table 3.

**Genes deregulated by TGF-β1 in LX-2 cells**

Several genes described in Table 1 have known roles in promoting HSC activation and liver fibrosis downstream of TGF-β1, including EGR2, FAP, FN1, HES1 and NOX4 [27–31]. While the function of these genes in relation to liver fibrosis is known, their highly upregulated status in this context may indicate that they are particularly significant.
mediators of early HSC activation or TGF-β1 signalling, and therefore worthy of more attention as potential markers for activating HSCs or fibrogenesis.

Other genes were identified in Table 1 that do not have clearly reported roles in HSCs. These genes have instead been associated with the activity of fibroblasts or fibrogenesis in other tissues, including FOXS1, TGFβI, PI16, VIP and PRG4. FOXS1 promotes the activation of primary human skin fibroblasts [32], while TGFβI has been shown to interact with ECM proteins, including collagen type 1 (COL1), to inhibit the cell-ECM adhesion of skin and scleral fibroblasts [33]. The upregulation of these genes seen here may indicate that FOXS1 also promotes HSC activation downstream of TGF-β1, while TGFβI is likely involved in facilitating the migration of early activating HSCs from the space of Dissé. The overexpression of PI16 has been shown to reduce the proliferation of, and expression of COL1 in, murine cardiac fibroblasts [34]. Similarly, the reduced expression of VIP correlates with progressive cardiac fibrosis in murine models, which can be reversed by VIP overexpression [35]. PRG4 is associated with protection functions in the connective tissues and reduced fibroblast activation in the synovial tissue [36]. Assuming these genes carry out similar functions in HSCs, their upregulation by TGF-β1 is indicative of negative regulation of HSC activation, likely as a means of controlling fibrosis progression.

Several downregulated genes whose function likely influences HSC activity were identified in Table 2, including CIITA, SERPINB2 and PSG1. The upregulation of CIITA results in the increased expression of major histocompatibility complex II (MHCII) genes [37], which have been shown to reduce HSC collagen expression and fibrotic potential during schistosomiasis infection [38]. It can therefore be assumed that the downregulated CIITA expression seen here would increase HSC collagen expression and contribution to fibrosis [38]. A deficiency of SERPINB2 in the livers of murine models of the helminth Schistosoma japonicum infection results in a reduction in the deposition of collagen within the egg-induced granuloma [39]. Given the role of HSCs within the granuloma, it is highly likely that SERPINB2 deficiency reduces HSC activity to bring about this effect and, if so, would implicate SERPINB2 as a promoter of HSC activity. PSG1 has been shown to stimulate the release of active TGF-β1 protein in vitro [40], and

| Gene ID | Gene name | Fold change | FDR      |
|--------|-----------|-------------|----------|
| ISLR2  | Immunoglobulin superfamily cont. leucine rich repeat 2 | 324.03 | 6.06E-11 |
| KRT3   | Keratin 3 | 56.49 | 1.71E-04 |
| FOXS1  | Forkhead box S1 | 54.19 | 1.18E-12 |
| PMEA1  | Prostate transmembrane protein, androgen induced 1 | 49.87 | 8.20E-279 |
| EGR2   | Early growth response 2 | 35.26 | 1.40E-65 |
| SYN1   | Synapsin I | 28.84 | 2.16E-06 |
| FAP    | Fibroblast activation protein | 26.17 | 5.84E-33 |
| SCN7A  | Sodium voltage-gated channel alpha subunit 7 | 21.26 | 3.76E-11 |
| STRA6  | Signalling receptor and transporter of retinol | 15.89 | 1.47E-07 |
| PI16   | Peptidase inhibitor 16 | 14.83 | 7.01E-07 |
| VIP    | Vasoactive intestinal peptide | 14.62 | 8.14E-03 |
| NOX4   | NADPH oxidase 4 | 14.22 | 1.08E-03 |
| LRRC15 | Leucine rich repeat containing protein 15 | 14.12 | 9.03E-39 |
| PRG4   | Proteoglycan 4 | 13.45 | 1.31E-03 |
| GAL    | Galanin and GMAP prepropeptide | 13.36 | 3.27E-05 |
| DSP    | Desmoplakin | 11.71 | 0.00E+00* |
| UNC5B  | Unc-5 netrin receptor B | 11.31 | 1.78E-09 |
| GUCY1A3| Guanylate cyclase soluble subunit alpha-3 | 10.34 | 6.82E-03 |
| KANK4  | KN motif and ankyrin repeat domains 4 | 9.85 | 1.18E-02 |
| TGFB1  | Transforming growth factor beta induced | 9.58 | 0.00E+00* |
| FN1    | Fibronectin 1 | 8.06 | 0.00E+00* |
| SLAMF8 | SLAM family member 8 | 7.16 | 3.95E-32 |
| HES1   | Hes family BHLH transcription factor 1 | 6.68 | 2.24E-55 |
| MICALCL| MICAL C-terminal like | 6.63 | 7.93E-07 |
| CCL7   | Chemokine (C-C motif) ligand 7 | 6.59 | 5.00E-08 |

* FDR value of 0.0 owing to a limitation in R software that returns values lower than 2.2E-308 as 0.0. These genes were assigned a FDR value of 1E-308 for pathway analysis.
Table 2  Genes downregulated by transforming growth factor-β1 (TGF-β1) in LX-2 cells

| Gene ID | Gene name                          | Fold change | FDR      |
|---------|------------------------------------|-------------|----------|
| SOX3    | SRY-box transcription factor 3     | −33.33      | 1.58E-03 |
| NR5A2   | Nuclear receptor subfamily 5 group A member 2 | −25.00      | 5.29E-06 |
| LRRC7   | Leucine rich repeat containing protein 7 | −16.67      | 2.56E-12 |
| SERPINB2| Serpin family B member 2           | −12.50      | 1.10E-52 |
| SEMA3B  | Semaphorin-3-B                     | −11.11      | 1.12E-15 |
| COL17A1 | Collagen type 17 α1 chain          | −11.11      | 2.76E-09 |
| VCAM1   | Vascular cell adhesion molecule 1  | −11.11      | 1.83E-05 |
| EVI2B   | Ecotropic viral integration site 2B| −10.00      | 4.53E-27 |
| ZNF665  | Zinc finger protein 665            | −9.09       | 1.22E-02 |
| PSG1    | Pregnancy specific β-1-glycoprotein 1 | −9.09      | 1.41E-02 |
| PTPRC   | Protein tyrosine phosphatase receptor type C | −7.69 | 1.25E-04 |
| SEMA3A  | Semaphorin-3 A                     | −7.69       | 1.84E-50 |
| SLC27A2 | Solute carrier family 27 member 2  | −7.14       | 9.88E-20 |
| EVI2A   | Ecotropic viral integration site 2 A | −7.14       | 1.32E-20 |
| PTPRN2  | Protein tyrosine phosphatase receptor type N2 | −6.67 | 1.65E-03 |
| MSTN    | Myostatin                          | −5.88       | 2.40E-11 |
| GRIA1   | Glutamate ionotropic receptor AMPA type subunit 1 | −5.88 | 5.08E-04 |
| PLEKHG4 | Pleckstrin homology and RhoGEF domain containing G4 | −5.88 | 5.91E-13 |
| COL4A6  | Collagen type 4 α6 chain           | −5.88       | 1.37E-12 |
| PPL     | Periplakin                          | −5.56       | 6.90E-41 |
| ADRA1B  | Alpha-1B adrenergic receptor       | −5.26       | 1.85E-05 |
| CHRM2   | Cholinergic receptor muscarinic 2   | −5.26       | 1.12E-14 |
| CIITA   | Class II major histocompatibility complex transactivator | −5.26 | 1.43E-02 |
| GALNT5  | Polypeptide N-acetylglactosaminyltransferase 5 | −5.26 | 4.83E-04 |
| GRIN2A  | Glutamate ionotropic receptor NMDA type subunit 2 A | −5.26 | 5.18E-100 |

Table 3  Summary of the deregulating effects of transforming growth factor-β1 (TGF-β1) on genes and pathways in LX-2 cells

| Gene    | Effect of TGF-β1 | Phenotype       | Pathway                        | Effect of TGF-β1 | Phenotype       |
|---------|------------------|-----------------|--------------------------------|------------------|-----------------|
| CIITA   | Downregulated    | Not characterised| Actin nucleation by ARP-WASP complex | Upregulated      | Activated       |
| COL17α1 | Downregulated    | Not characterised| Apelin signalling              | Downregulated    | Activated       |
| COL4α6  | Downregulated    | Not characterised| EIF2 signalling                | Upregulated      | Activated       |
| EGR2    | Upregulated      | Activated       | ERK5 signalling                | Upregulated      | Activated       |
| FAP     | Upregulated      | Activated       | Ethanol degradation            | Downregulated    | Activated       |
| FN1     | Upregulated      | Activated       | PI3K/AKT signalling            | Upregulated      | Activated       |
| FOXS1   | Upregulated      | Not characterised| PPAR signalling                | Downregulated    | Quiescent       |
| HES1    | Upregulated      | Activated       | PPARα/RXRα activation          | Downregulated    | Quiescent       |
| NOX4    | Upregulated      | Activated       | PTEN signalling                | Downregulated    | Quiescent       |
| PI16    | Upregulated      | Not characterised| STAT3 signalling               | Upregulated      | Activated       |
| PRG4    | Upregulated      | Not characterised| tRNA charging                  | Upregulated      | Activated       |
| PSG1    | Downregulated    | Not characterised| Unfolded protein response      | Upregulated      | No effect       |
| SEMA3A  | Downregulated    | Not characterised|                            |                  |                 |
| SERPINB2| Downregulated    | Not characterised|                            |                  |                 |
| TGFβ1   | Upregulated      | Not characterised|                            |                  |                 |
| VCAM1   | Downregulated    | Not characterised|                            |                  |                 |
| VIP     | Upregulated      | Not characterised|                            |                  |                 |

The deregulating effects of TGF-β1 on the genes and signalling pathways discussed above, and the result of this deregulation on the activation status of hepatic stellate cells (HSCs). Genes whose role within HSCs is unknown are listed as “not characterised”
therefore its reduced expression in this context would inhibit TGF-β1 signalling and subsequent HSC activation.

The expression of COL17A1 and COL4A6 were also downregulated, despite COL4 having been shown previously to be upregulated in HSCs following TGF-β1 exposure [41]. One previous study has shown that COL17 and COL4 interact in skin and oral keratinocytes to assist cell-ECM adhesion [42]. COL4 has been identified as an ECM component in the space of Dissé, the storage site of quiescent HSCs, while COL17 is a transmembrane collagen that interacts with both extra- and intracellular structural components to facilitate cell linkage to the epithelium. Given that activating HSCs must migrate from the space of Dissé towards the provoking stimuli, it is possible that the expression of these collagens, perhaps working in tandem with TGFβI, might be initially downregulated in order to allow the cell to disengage from the anchoring ECM in the space of Dissé, and thus allow migration.

**Signalling pathways upregulated by TGF-β1 in LX-2 cells**

The most strongly upregulated signalling pathway in Fig. 3 was that of transfer (t)-RNA charging, a pathway involved with protein translation. Increased tRNA charging activity is synonymous with the increased level of protein synthesis that occurs in HSCs during, and following, activation [5]. Similarly, eukaryotic translation initiation factor 2 (EIF2) signalling is important in the initiation of protein synthesis in eukaryotic cells [5]. However, one study has reported that a component of the S. mansoni EIF2 signalling pathway, the subunit EIF2α, can interact with the TGF-β receptors TGFβRI and TGFβRII to inhibit TGF-β signalling [43]. The nature of the enhanced EIF2 signalling in aHSCs following TGF-β1 exposure could therefore also double as a negative regulator of TGF-β1 responses.

Several pathways in Fig. 3, including ERK5, PI3K/AKT and STAT3 signalling, represent signalling pathways downstream of TGF-β1 that are capable of driving HSC activation [44]. TGF-β1 carries out physiological functions by inducing cellular gene expression, and the SMAD family of transcriptional regulators are generally responsible for transducing signals from TGF-β ligands to the cell nucleus [10]. The absence of such signalling from the data could suggest that, while highly active immediately following TGF-β1 exposure, the 24-hour timepoint SMAD signalling gives way to these alternative, SMAD-independent pathways. This likely occurs to balance preventing excessive HSC activation whilst simultaneously inducing pro-fibrotic gene expression in aHSCs.

The assembly of organised ACTA2 filaments is a strong marker of myofibroblasts [5] (see Fig. 1). These filaments carry out several functions in aHSCs, including supporting the expanding cell cytoplasm, facilitating cell motility and acting as a method of attaching to, and signalling between, the ECM and other cells [5, 45]. Therefore, it is unsurprising that the activity of the actin nucleation by ARP-WASP complex was upregulated by TGF-β1 exposure.

**Signalling pathways downregulated by TGF-β1 in LX-2 cells**

The most strongly downregulated signalling pathway in Fig. 4 was that of PPARα/RXRα activation, and PPAR signalling was also found to be downregulated. Quiescent HSCs take up and store vitamin A (retinol) within lipid droplets [5] following its metabolism into lipid-soluble derivatives [46]. HSCs regulate the expression of genes involved in fatty acid uptake and metabolism via peroxisome proliferator-activated receptors (PPARs) and the retinoid X receptor (RXR), which heterodimerise together to act as a transcription factor for these genes [46]. Upon activation, HSCs lose the ability to store vitamin A and, as such, display reduced retinol-related signalling [47]. Studies have shown that the expression of both PPAR-γ, a relative of PPAR-α, and RXR are reduced in aHSCs [47, 48]. Furthermore, agonism of PPAR-γ signalling in aHSCs has been shown to suppress the expression of ACTA2 and collagen type 1α1 (COL1A1), and to facilitate aHSC reversion back into a quiescent state [48]. As such, the downregulated activity of the PPARα/RXRα activation and PPAR signalling pathways following TGF-β1 exposure was expected.

Apelin is an endogenous ligand of the G protein-coupled API receptor. In the liver, apelin signalling is strongly associated with fibrosis; several studies have highlighted how components of the apelin signalling pathway induce the expression of pro-fibrotic genes in LX-2 cells, including COL1, ACTA2 and platelet-derived growth factor receptor-β (PDGFRβ) [49]. Furthermore, the inhibition of apelin signalling has been shown to reduce the intensity and burden of liver fibrosis in murine models [50]. Paradoxically however, other studies have linked apelin signalling with the inhibition of TGF-β1 responses; one study has shown that apelin inhibits the TGF-β1-induced activation of SMAD proteins and subsequent upregulation of ACTA2, COL1 and FN1 expression in epithelial cells [51], while another describes how apelin inhibits the TGF-β1-induced upregulation of ACTA2 and COL1A1 expression in cardiac fibroblasts [52]. These findings highlight the tissue-specific nature of apelin signalling and could indicate an interesting situation in HSCs whereby apelin increases fibrotic gene expression whilst simultaneously inhibiting TGF-β1 signalling.

Phosphatase and tensin homolog (PTEN) is a tumour suppressor protein that regulates cell cycle progression. Several studies have shown that PTEN signalling inhibits HSC activation; one study demonstrated that the downregulation of
miR-181b, an inhibitor of PTEN expression, results in the suppression of HSC activation as determined by reduced ACTA2 expression and collagen deposition [53]. Another study showed that PTEN-deficient mice develop progressive liver fibrosis characterised by the increased expression of ACTA2, COL1 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 [54]. HSCs isolated from these PTEN-deficient mice displayed higher levels of activation on average compared to HSCs in wild type mice [54]. Similarly, one final study has described how the overexpression of PTEN in rat HSCs prevents the morphological changes associated with activation, and reduces the expression of ACTA2 and COL1A1 [55]. Taken together, PTEN signalling is a strong negative regulator of HSC activation.

Ethanol and its metabolites have been shown to promote HSC activation through several mechanisms [56]. Given the strong activating influence of ethanol and acetaldehyde in HSCs, it is unusual that TGF-β1 exposure would downregulate the activity of several ethanol degradation pathways. HSCs express enzymes involved in ethanol degradation; however, it is possible that activated HSCs may inhibit the expression of these enzymes in an attempt to regulate ethanol-induced activation and fibrosis as a protective mechanism.

Conclusions

Our findings highlight the most strongly deregulated genes and signalling pathways in LX-2 cells in the early response to TGF-β1. While several of the genes identified are known influencers of HSC activation, many have not thoroughly characterised role in HSCs and their relevance to fibrosis was inferred from activities in other cell types and tissues. Characterising the role of these genes within HSCs could be a useful point for further study in order to identify any genes with novel roles in HSC activation.

As expected, TGF-β1 influenced signalling pathway activity in a direction that favoured HSC activation. Broadly speaking, most of the pathways upregulated by TGF-β1 can be categorised according to their involvement in either SMAD-independent transcriptional regulation, protein translation regulation, or regulation of the actin cytoskeleton. Conversely, the pathways downregulated by TGF-β1 cover a broader range of signalling processes that are harder to categorise. While we did not identify any novel fibrosis-associated processes occurring within LX-2 cells, the identification of the specific pathways most involved in the early LX-2 cell response to TGF-β1 is useful for the improved understanding of the impacts of TGF-β1 signalling in HSCs.

Acknowledgements The support of the Genomics Central Technology Unit (GCTU) of Queen’s University Belfast is acknowledged.

Authors' contributions Design of experiments by JPC and GNG. Analysis of data by JPC and GNG. First draft of manuscript by JPC, and subsequent drafting by JPC, MWR, GAR and GNG. All authors read and approved the final manuscript.

Funding JPC is a recipient of a studentship from the Department of Education and Learning (DEL) Northern Ireland. GAR is supported by a fellowship from the NHMRC Australia. GNG is supported by a QUB FMHLS CTU Pilot Project Grant.

Data Availability The dataset generated during the current study is available in the National Center for Biotechnology Information (NCBI) repository (BioProject PRJNA680982, available at https://www.ncbi.nlm.nih.gov/bioproject/PRJNA680982).

Code availability Not applicable.

Declarations

Conflict of interest The authors declare that they have no competing interests.

Ethical approval Not applicable.

Consent to participate Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Dewidar B, Meyer C, Dooley S, Meinidl-Beinker N (2019) TGF-β in hepatic stellate cell activation and liver fibrogenesis. Cells 8:1419. https://doi.org/10.3390/cells8111419
2. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: Immune regulation of wound healing in a solid organ. Nat Rev Immunol 14:181–194. https://doi.org/10.1038/nri3623
3. Ni Y, Li JM, Liu MK, Zhang TT, Wang DP, Zhou WH, Hu LZ, Lv WL (2017) Pathological process of liver sinusoidal endothelial cells in liver diseases. World J Gastroenterol 23:7666–7677. https://doi.org/10.3748/wjg.v23.i43.7666
4. Elpek G (2014) Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update. World J Gastroenterol 20:7260–7276. https://doi.org/10.3748/wjg.v20.i23.7260
5. Friedman SL (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88:125–172. https://doi.org/10.1152/physrev.00013.2007
6. Geerts A (2001) History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21:311–336. https://doi.org/10.1055/s-2001-17550
7. Weiskirchen R, Tacke F (2014) Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg Nutr 3:344–363. https://doi.org/10.3978/j.issn.2304-3881.2014.11.03

8. Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Publ Gr 14:397–411. https://doi.org/10.1038/nn gastro.2017.38

9. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA (1999) The role of TGFβ1 in initiating hepatic stellate cell activation in vivo. J Hepatol 30:77–87. https://doi.org/10.1016/S0168-8278(99)80010-5

10. Biernacka A, Dobaczewski M, Frangogiannis NG (2011) TGF-β signaling in fibrosis. Growth Factors 29:196–202. https://doi.org/10.3109/08977194.2011.595714

11. Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng JF (2005) Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54:142–151. https://doi.org/10.1136/gut.2004.042127

12. Fabre T, Kared H, Friedman SL, Shoukry NH (2014) IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-β receptor on hepatic stellate cells in a JNK-dependent manner. J Immunol 193:3925–3933. https://doi.org/10.4049/jimmunol.1400861

13. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29:15–21. https://doi.org/10.1093/bioinformatics/bts635

14. Anders S, Pyl PT, Huber W (2015) HTSeq-A Python framework for work with high-throughput sequencing data. Bioinformatics 31:166–169. https://doi.org/10.1093/bioinformatics/btu638

15. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https://doi.org/10.1186/s13059-014-0550-8

16. R Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.

17. Qiagen Inc. https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis.

18. Krämer A, Green J, Pollard J, Tugendreich S (2014) Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30:523–530. https://doi.org/10.1093/bioinformatics/btt703

19. Higashi T, Friedman SL, Hoshida Y (2017) Hepatic stellate cells as key target in liver fibrosis. 121:27–42. https://doi.org/10.1016/j.bdbbp.2017.05.007

20. Li QX, Ren ZX, Li K, Huang JJ, Huang ZT, Zhou TR, Cao HY, Zhang FX, Tan B (2017) Key anti-fibrosis associated long non-coding rnas identified in human hepatic stellate cell via transcriptome sequencing analysis. Int J Mol Sci 19:. https://doi.org/10. 3390/ijms19030675

21. Zhou C, York SR, Chen JY, Pondick JV, Motola DL, Chung RT, Mullen AC (2016) Long noncoding RNAs expressed in human hepatic stellate cells form networks with extracellular matrix proteins. Genome Med 8:1–20. https://doi.org/10.1186/s13073-016-0285-0

22. Xiong WJ, Hu LJ, Jian YC, Wang LJ, Jiang M, Li W, He Y (2012) Wnt5a participates in hepatic stellate cell activation observed by gene expression profile and functional assays. World J Gastroenterol 18:1745–1752. https://doi.org/10.3748/wjg.v18.i15.1745

23. Guo CJ, Xiao X, Sheng L, Chen L, Zhong W, Li H, Hua J, Ma X (2017) RNA sequencing and bioinformatics analysis implicate the regulatory role of a long noncoding RNA-mRNA network in hepatic stellate cell activation. Cell Physiol Biochem 42:2030–2042. https://doi.org/10.1159/000479898

24. Shimada H, Ochi T, Imasato A, Morizane Y, Hori M, Ozaki H, Shinjo K (2010) Gene expression profiling and functional assays of activated hepatic stellate cells suggest that myocardin has a role in activation. Liver Int 30:42–54. https://doi.org/10.1111/j.1478-3239.2009.02120.x

25. Gerhard GS, Davis B, Wu X, Hanson A, Wilhelmsen D, Piras IS, Still CD, Chu X, Petrick AT, DiStefano JK (2020) Differentially expressed mRNAs and IncRNAs shared between activated human hepatic stellate cells and nash fibrosis. Biochem Biophysics Reports 22:. https://doi.org/10.1016/j.bbrep.2020.100753

26. Kaftanovskaya EM, Ng HH, Soula M, Rivas B, Myhr C, Ho BA, Cervantes BA, Shupe TD, Defarassetty M, Hu X, Xu X, Patnaik S, Wilson KJ, Barnaeva E, Ferrer M, Southall NT, Marugan JJ, Bishop CE, Agoulnik IU, Agoulnik AI (2019) Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. FASEB J 33:12435. https://doi.org/10.1096/fj.201901046R

27. Zhang K, Zhang YQ, Ai WB, Hu QT, Zhang QJ, Wan LY, Wang XL, Liu CB, Wu JF (2015) Hes1, an important gene for activation of hepatic stellate cells, is regulated by Notch1 and TGF-β/BMP signaling. World J Gastroenterol 21:878–887. https://doi.org/10.3748/wjg.v21.i3.878

28. Liu XY, Liu RX, Hou F, Cui JJ, Li CY, Chi C, Yi E, Wen Y, Yin CH (2016) Fibronectin expression is critical for liver fibrogenesis in vivo and in vitro. Mol Med Rep 14:3669–3675. https://doi.org/10.3892/mmr.2016.5673

29. Sancho P, Mainée J, Crosas-Molist E, Roncero C, Fernández-Rodríguez CM, Pinedo F, Huber H, Eferli R, Mikulits W, Fabregat I (2012) NADPH Oxidase NOX4 Mediates Stellate Cell Activation and Hepatocyte Cell Death during Liver Fibrosis Development. PLoS One 7:. https://doi.org/10.1371/journal.pone.0045285

30. Wang XM, Yu DMT, McLaughan GW, Gorrell MD (2005) Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 42:935–945. https://doi.org/10.1002/hep.20853

31. Vollmann EH, Cao L, Amatucci G, Reynolds T, Hamann S, Dalkilic-Liddle I, Cameron TO, Duffield J, Burky LC, Hossbach M, Kaufmann KJ, Mir FF, Anderson DG, Novobrantseva T, Koteliansky V, Kisseleva T, Brenner D (2017) Identification of novel fibrosis modifiers by in vivo siRNA silencing. Mol Ther - Nucleic Acids 7:314–323. https://doi.org/10.1016/j.omtn.2017.04.014

32. Noizet M, Lagoutte E, Gratigny M, Bouschbacher M, Lazareth I, Roest Crollius H, Darazacq X, Dugast-Darazacq C (2016) Master regulators in primary skin fibroblast fate reprogramming in a human ex vivo model of chronic wounds. Wound Repair Regen 24:247–262. https://doi.org/10.1111/wrr.12392

33. Duggan KA, Hodge G, Chen J, Hunter T (2019) Vasoactive intestinal peptide infusion reverses existing myocardial fibrosis in the rat. Eur J Pharmacol 862:. https://doi.org/10.1016/j.ejphar.2019.172629

34. Qadri M, Jay GD, Zhang LX, Richendrfer H, Schmidt TA, Elsaid MY (2020) Proteoglycan-4 regulates fibroblast to myofibroblast transition and expression of fibrogenic genes in the synovium. Arthritis Res Ther 22:113. https://doi.org/10.1186/s13075-020-02207-x

35. Devaiah BN, Singer DS (2013) CIITA and its dual roles in MHC class II gene expression. Front Immunol 4:. https://doi.org/10.3389/fimmu.2013.00476

36. Zhou CL, Kong DL, Liu JF, Lu ZK, Guo HF, Wang W, Qiu JF, Liu XJ, Wang Y (2017) MHC II-, but not MHC II+, hepatic stellate cells contribute to liver fibrosis of mice in infection with...
Schistosoma japonicum. Biochim Biophys Acta - Mol Basis Dis 1863:1848–1857. https://doi.org/10.1016/j.bbadis.2017.05.002

39. Schroder WA, Gardner J, Le TT, Duke M, Burke ML, Jones MK, McManus DP, Suhrbier A (2010) SerpinB2 deficiency modulates Th1/Th2 responses after schistosome infection. Parasite Immunol 32:764–768. https://doi.org/10.1111/j.1365-3024.2010.01241.x

40. Blois SM, Sulkowski G, Tirado-González I, Warren J, Freitag N, Klapp BF, Rittik D, Fuss I, Strober W, Dveksler GS (2014) Pregnancy-specific glycoprotein 1 (PSG1) activates TGF-β and prevents dextran sodium sulfate (DSS)-induced colitis in mice. Mucosal Immunol 7:348–358. https://doi.org/10.1038/mi.2013.53

41. Fullár A, Firneisz G, Regős E, Dudás J, Szarvas T, Baghy K, Ramadori G, Kovalszky I (2017) Response of hepatic stellate cells to TGFB1 differs from the response of myofibroblasts. Decorin protects against the action of growth factor. Pathol Oncol Res 23:287–294. https://doi.org/10.1007/s12253-016-0095-0

42. Kamaguchi M, Iwata H, Nishie W, Toyonaga E, Ujiie H, Natsuga K, Kitagawa Y, Shimizu H (2019) The direct binding of collagen XVII and collagen IV is disrupted by pemphigoid autoantibodies. Pathol Oncol Res 23:287–294. https://doi.org/10.1007/s12253-016-0095-0

43. McGonigle S, Beall MJ, Pearce EJ (2002) Eukaryotic initiation factor 2α subunit associates with TGFβ receptors and 14-3-3ε and acts as a modulator of the TGFβ response. Biochemistry 41:579–587. https://doi.org/10.1021/bi011407z

44. Kagan P, Sultan M, Tachlytski I, Safran M, Ben-Ari Z, Anhuf D (2017) Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation. PLoS One 12:e0176173. https://doi.org/10.1371/journal.pone.0176173

45. Carpenter CL (2000) Actin cytoskeleton and cell signaling. Crit Care Med 28:94–99. https://doi.org/10.1097/00003246-200004001-00011

46. Hellemans K, Rombouts K, Quartier E, Dittie AS, Knorr A, Michalik L, Rogiers V, Schuit F, Wahli W, Geerts M (2003) PPARβ regulates vitamin A metabolism-related gene expression in hepatic stellate cells undergoing activation. J Lipid Res 44:250–259. https://doi.org/10.1194/jlr.M20376-JLR200

47. Ohata M, Lin M, Satre M, Tsukamoto H (1997) Diminished retinoic acid signaling in hepatic stellate cells in cholestatic liver fibrosis. Am J Physiol - Gastrointest Liver Physiol 272:. https://doi.org/10.1152/ajpgi.1997.272.3.g589

48. Miyahara T, Schrum L, Rippe R, Xiong S, Yee J, Motomura K, Anania FA, Willson TM, Tsukamoto H (2000) Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275:35715–35722. https://doi.org/10.1074/jbc.M006577200

49. Melgar-Lemes P, Casals G, Pauta M, Ros J, Reichenbach V, Bataller R, Morales-Ruíz M, Jimenez W (2010) Apelin mediates the induction of profibrogenic genes in human hepatic stellate cells. Endocrinology 151:5306–5314. https://doi.org/10.1210/en.2010-0754

50. Reichenbach V, Ros J, Fernández-Varo G, Casals G, Melgar-Lemes P, Campos T, Makriyannis A, Morales-Ruíz M, Jimenez W (2012) Prevention of fibrosis progression in CCl 4-Treated rats: Role of the hepatic endocannabinoid and apelin systems. J Pharmacol Exp Ther 340:629–637. https://doi.org/10.1124/jpet.111.188078

51. Wang LY, Diao ZL, Zheng JF, Wu YR, Zhang QD, Liu WH (2017) Apelin attenuates TGF-β1-induced epithelial to mesenchymal transition via activation of PKC-ε in human renal tubular epithelial cells. Peptides 96:44–52. https://doi.org/10.1016/j.peptides.2017.08.006

52. Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guillemin-Fringer C, Schara S, Seguela MH, Waneq E, Valet P, Parini A, Kunduzova O (2012) Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J 33:2360–2369. https://doi.org/10.1093/eurheartj/eht389

53. Geng W, Zhou G, Zhao B, Xiao Q, Li C, Fan S, Dong P, Zheng J (2020) Liquiritinigem suppresses the activation of hepatic stellate cells via targeting miR-181b/PTEN axis. Phytomedicine 66:. https://doi.org/10.1016/j.phymed.2019.153108

54. He L, Gubbins J, Peng Z, Medina V, Fei F, Ashahina K, Wang I, Kahn M, Rountree CB, Stiles BL (2016) Activation of hepatic stellate cell in Pten null liver injury model. Fibrogenes Tissue Repair 9:. https://doi.org/10.1186/s13069-016-0045-1

55. Takashima M, Parsons CJ, Ikejima K, Watanabe S, White ES, Rippe RA (2009) The tumor suppressor protein PTEN inhibits rat hepatic stellate cell activation. J Gastroenterol 44:847–855. https://doi.org/10.1007/s00535-009-0073-3

56. Wang JH, Batey RG, George J (2006) Role of ethanol in the regulation of hepatic stellate cell function. World J Gastroenterol 12:6926–6932. https://doi.org/10.3748/wjg.v12.i43.6926

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.